

Lupin launches Generic PhosLo in the US

28 October 2015 | News | By BioSpectrum Bureau

Lupin launches Generic PhosLo in the US



Pharma major Lupin has announced that its US subsidiary, Lupin Pharmaceuticals Inc. (collectively Lupin) has launched its Calcium Acetate Capsules, 667 mg (eq. 169 mg Calcium) having received final approval from the United States Food and Drug Administration (FDA).

Lupin's Calcium Acetate Capsules, 667 mg (eq. 169 mg Calcium) are the AB rated generic equivalent of Fresenius Medical Care North America's (Fresenius) PhosLo Gelcaps 667 mg (eq. 169 mg Calcium) and are indicated for the control of hyperphosphatemia in end stage renal failure.

PhosLo Gelcaps had annual US sales of \$54.5 million (IMS MAT March, 2015).